Pharminent

Amgen and Arrowhead to develop gene-therapies for heart disease

(Reuters) – Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and team up with the company to develop gene-silencing therapies for heart disease.
http://www.reuters.com/article/us-amgen-arrowhead-idUSKCN11Z1F3

Filed under: Cardiovascular